

## Clinical Policy: Nusinersen (Spinraza)

Reference Number: ERX.SPA.10

Effective Date: 04.01.17

Last Review Date: 08.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

### Description

Nusinersen (Spinraza®) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide.

### FDA Approved Indication(s)

Spinraza is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

*Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.*

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Spinraza is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Spinal Muscular Atrophy (must meet all):

1. Diagnosis of SMA;
2. Genetic testing confirms the presence of one of the following (a, b, or c):
  - a. Homozygous deletions of SMN1 gene (e.g., absence of the SMN1 gene);
  - b. Homozygous mutation in the SMN1 gene (e.g., biallelic mutations of exon 7);
  - c. Compound heterozygous mutation in the SMN1 gene (e.g., deletion of SMN1 exon 7 [allele 1] and mutation of SMN1 [allele 2]);
3. Prescribed by or in consultation with a neurologist;
4. Documentation of genetic testing quantifying number of copies of SMN2 gene and one of the following (a and b):
  - a. One, two, or three copies of SMN2 gene;
  - b. Four copies of SMN2 gene, and documentation indicates presence of SMA symptoms (e.g. weakness, tremor, loss of functionality);
5. Documentation of one of the following baseline scores (*see Appendix D*) (a or b):
  - a. For age < 2 years: Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorder (CHOP-INTEND) score or Hammersmith Infant Neurological Examination (HINE) Section 2 motor milestone score;
  - b. For age ≥ 2 years: Hammersmith functional motor scale expanded (HFMSE) score, Revised Hammersmith Scale (RHS), Upper Limb Module (ULM), Revised Upper Limb Module (RULM), or 6-Minute Walk Test (6MWT);
6. Member does not require tracheostomy or invasive or noninvasive ventilation for ≥ 16 hours/day continuously for > 21 days;
7. Failure\* of Evrysdi®, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Failure will be defined as decline in motor function test score(s) from baseline*
8. Spinraza is not prescribed concurrently with Evrysdi or Zolgensma®;
9. If the member is currently on Evrysdi, documentation of prescriber attestation of Evrysdi discontinuation;
10. If the member has a history of treatment with Zolgensma, must meet the following

- (a and b):
- a. Provider must submit evidence of poor response to Zolgensma (e.g., sustained decrease in CHOP-INTEND score over a period 6 months);
  - b. Documentation of provider attestation of clinical deterioration;
11. Total dose does not exceed 4 doses of 12 mg, prescribed for intrathecal use.

**Approval duration: 12 months (up to 4 doses)**

**B. Other diagnoses/indications**

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**II. Continued Therapy**

**A. Spinal Muscular Atrophy** (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member does not require tracheostomy or invasive or noninvasive ventilation for  $\geq 16$  hours/day continuously for  $> 21$  days;
3. Member is responding positively to therapy, as evidenced by one of the following (a, b, or c):
  - a. For age  $< 2$  years, one of the following (i or ii):
    - i. For CHOP-INTEND, must demonstrate score improvement or maintenance of previous score improvement of  $\geq 4$  points from baseline;
    - ii. For HINE motor milestone score, must demonstrate score improvement or maintenance of previous improvement in one or more categories AND improvement in more motor milestone categories than worsening;
  - b. For age  $\geq 2$  years, one of the following (i, ii, or iii):
    - i. If first renewal since turning 2 years old, must provide submission of baseline HFMSE score, RHS score, RULM or ULM score, or 6MWT distance AND meet one of the following (1 or 2):
      - 1) For CHOP-INTEND, must demonstrate score improvement or maintenance of previous score improvement of  $\geq 4$  points from baseline;
      - 2) For HINE motor milestone score, must demonstrate score improvement or maintenance of previous improvement in one or more categories AND improvement in more motor milestone categories than worsening;
    - ii. If  $\leq 2$  years at therapy initiation and request is for subsequent renewal since turning 2, must meet one of the following (*see Appendix D*) (1 or 2):
      - 1) For HFMSE, RHS, ULM or RULM, must demonstrate score improvement or maintenance of previous score improvement from baseline score submitted at first renewal since turning 2 years old;
      - 2) For 6MWT distance, must demonstrate improvement or maintenance of baseline distance;
    - iii. If  $> 2$  years at therapy initiation, must meet one of the following (*see Appendix D*) (1, 2, 3, or 4):
      - 1) For HFMSE or RHS, must demonstrate score improvement or maintenance of previous score improvement of  $\geq 3$  points from baseline;
      - 2) For ULM, must demonstrate score improvement or maintenance of previous improvements in  $\geq 2$  points from baseline;
      - 3) For RULM, must demonstrate score improvement or maintenance of previous improvements in  $\geq 4$  points from baseline;
      - 4) For 6MWT distance, must demonstrate improvement or maintenance of baseline distance;
  - c. Member has not had a decline in motor function test score(s) from baseline AND medical justification demonstrates and supports that member is responding positively to therapy;
4. Spinraza is not prescribed concurrently with Evrysdi or Zolgensma;
5. If request is for a dose increase, new dose does not exceed 12 mg every 4 months prescribed for intrathecal use.

**Approval duration: 12 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less);** or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CHOP-INTEND: Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorder

FDA: Food and Drug Administration

HFMSE: Hammersmith Functional Motor Scale Expanded

HINE: Hammersmith Infant Neurological Examination

MPLA: multiplex ligation-dependent probe amplification

RHS: Revised Hammersmith Scale

RULM: Revised Upper Limb Module

SMA: spinal muscular atrophy

SMN: survival motor neuron

ULM: Upper Limb Module

6MWT: 6-Minute Walk Test

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Evrysdi® (risdiplam)	Weight-based dose PO QD: <ul style="list-style-type: none"> <li>• 2 months to less than 2 years of age: 0.2 mg/kg</li> <li>• 2 years of age and older, weighing less than 20 kg: 0.25 mg/kg</li> <li>• 2 years of age and older, weigh 20 kg or more: 5 mg</li> </ul>	5 mg/day

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

None reported

*Appendix D: General Information*

- SMA is an autosomal recessive genetic disorder. It is caused by mutations in the SMN1 (survival motor neuron) gene that is found on chromosome 5 (hence the name 5q-SMA). To develop SMA, an individual must inherit two faulty (deletion or mutation) SMN1 genes, one from each parent.
- There are other types of SMA that are not related to chromosome 5 or SMN. Safety and efficacy of Spinraza in non-SMN-related SMA has not been established.
- SMN-related SMA is classified as type 1 through 4 depending on time of onset. The age of disease onset of symptoms correlates with disease severity: the earlier the age of onset, the greater the impact on motor function. Children who display symptoms at birth or in infancy typically have the lowest level of functioning (type 1). SMA onset in children (types 2 and 3), teens or adults (type 4) generally correlates with increasingly higher levels of motor function.
- Efficacy of Spinraza was established primarily in infantile disease (SMA type 1). Spinraza was approved based on interim results of an unpublished Phase III study of patients with spinal muscular atrophy type I (infantile-onset). The phase III study, referred to as ENDEAR, enrolled

infants diagnosed with symptomatic, genetically confirmed spinal muscular atrophy (SMA) type I with two copies of SMN2 gene. Key inclusion criteria were: genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation or compound heterozygote, onset of clinical signs and symptoms consistent with SMA at  $\leq 6$  months, at study entry, receiving adequate nutrition and hydration) with or without gastrostomy), seven month of age or younger at screening, body weight  $\geq 3^{\text{rd}}$  percentile for age, and gestational age of 37 to 42 weeks. Key exclusion criteria were: hypoxemia and signs or symptoms of SMA present at birth within the 1<sup>st</sup> week after birth.

- Based on the mechanism of action of Spinraza, SMN2 must be present in sufficient amount for the production of full length SMN protein required to alleviate or minimize the symptoms of SMA.
- All subjects in the ENDEAR study had at least 2 copies of SMN2 genes (98% of the subjects in the pivotal study had 2 copies of SMN2 genes, while other had 3 or 4 copies).
- It is unknown whether patients with less than 2 copies would make sufficient SMN protein to mitigate the symptoms of SMA as the efficacy of this agent has not been demonstrated in patients with less than 2 copies of SMN2 genes.
- SMN2 gene copy and SMA types:
  - SMN2 gene copy numbers are variable in individuals with spinal muscular atrophy. Higher numbers typically correlate with less severe disease.
  - More than 95% of individuals with spinal muscular atrophy retain at least 1 copy of the SMN2 gene.
  - About 80% of individuals with Type I spinal muscular atrophy have 1 or 2 copies of the SMN2 gene.
  - About 82% of individuals with Type II spinal muscular atrophy have 3 copies of the SMN2 gene.
  - About 96% of individuals with Type III spinal muscular atrophy have 3 or 4 copies of the SMN2 gene.
- The CHOP-INTEND score is a validated 16-item, 64-point scale shown to be reliable and sensitive to change over time for SMA Type 1. In a prospective cohort study of SMA type I patients (n = 34), the mean rate of decline in the CHOP-INTEND score was 1.27 points/year (95% CI 0.21-2.33, p = 0.02).
- The HINE Section 2 motor milestone exam is an easily performed and relatively brief standardized clinical neurological examination that is optimal for infants aged between 2 and 24 months with good inter-observer reliability. This endpoint evaluates seven different areas of motor milestone development, with a maximum score between 2-4 points for each, depending on the milestone, and a total maximum score of 26 points.
- The HFSME score combines the Hammersmith Functional Motor Scale with a 13-item expansion module for ability to distinguish motor skills among individuals who may be older or with SMA types II and III. Each item is graded from 0 to 3, with 0 signifying no response, with a total of 66 points. HFMSE has demonstrated reliability and validity in patients with SMA. An increase of greater than 2 points in total score is unlikely in untreated SMA.
- The RHS is an ordinal scale which consist of 33 items with grades of 0, 1, and 2. For individuals who can achieve the task without any compensation it is given a score of 2. For those who only attempt the movement or finish it with some form of compensation is scored 1 and score of 0 is given when patients are unable to perform any part of the item. The total maximum score is 69 points.
- The RULM is a set of 19 tasks that measure motor function in non-ambulatory SMA patients. Each task is assessed with a 3 point ordinal scale, with a total maximum score of 37 points. Meanwhile, the maximum score for ULM was 18.
- The 6MWT is a clinical outcome measure for ambulatory SMA that has been determined to be functionally meaningful and capable of capturing disease severity.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
SMA	<p><b>Initial</b> (4 loading doses): 12 mg intrathecally every 14 days for 3 doses (loading doses); then, a fourth loading dose of 12 mg intrathecally 30 days after the third loading dose</p> <p><b>Maintenance:</b> 12 mg intrathecally every 4 months</p>	12 mg intrathecally every 4 months

**VI. Product Availability**

Solution for intrathecal injection: 12 mg/5 mL

**VII. References**

- Spinraza Prescribing Information. Cambridge, MA: Biogen Inc.; June 2020. Available at: <https://www.spinraza-hcp.com/>. Accessed August 20, 2020.
- Wang CH, Finkel RS, Bertini ES, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. *Journal of Child Neurology* 2007; 22:1027-1049.
- Cobben JM, de Visser M, Scheffer H, et al. Confirmation of clinical diagnosis in requests for prenatal prediction of SMA type I. *J Neurol Neurosurg Psychiatry* 1993; 56: 319-21.
- Maitre NL, Chorna O, Romeo DM, and Guzzetta A. Implementation of the Hammersmith Infant Neurological Examination in a High-Risk Infant Follow-Up Program. *Pediatric Neurology* 2016; 65:31-38.
- Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. *N Engl J Med* 2017; 377:1723-32. DOI: 10.1056/NEJMoa1702752
- Finkel RS, Chiriboga CA, Day JW, et al. Treatment of Infantile-Onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-Label, Dose-Escalation Study. *The Lancet* 2016;16:31408-8.
- Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. *N Engl J Med* 2018; 378:625-35. DOI: 0.1056/NEJMoa1710504
- Darras BT, Royden Jones H Jr, Ryan MM, et al. *Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach*. 2nd ed. London, UK: Elsevier; 2015.
- Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. *Neurology* 2014; 83:810-817.
- Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. *Muscle and Nerve*. 2016. 54: 836-842.
- Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for Spinal Muscular Atrophy: A SMA Specific Clinical Outcome Assessment Tool. *PLoS ONE*. 2017; 12(2): e0172346. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0172346>

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	01.17	02.17
Initial approval criteria: added three or four copies of SMN2	01.24.17	02.15.17
Revisions: Initial criteria: Updated # of copies of SMN2 from 3,4,or 5 to 1 or 2 copies Changed diagnosis of SMA type I to sxs of SMA before 6 months of age Removed criterion for SMA type IV Updated specialist requirement to pediatric neurologist Added HFMSE baseline score for age >2 yo Continuation criteria: Specifically divided up positive response to tx via HINE or HFMSE score based on age Added requirement of number of categories of improvement and decline language	03.07.17	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q18 annual review: Converted to new template. Expanded indication to SMA types 1-3 with SMN2 copies up to 4.	11.28.17	02.18
Added CHOP-INTEND score as an allowable tool to measure motor function for members < 2 years of age; allowed maintenance (in addition to improvement) from baseline CHOP-INTEND, HINE, or HFMSE score for continued approval; removed requirement for documentation of number of categories of improvement for continued approval; references reviewed and updated.	05.08.18	08.18
1Q 2019 annual review: no significant changes; references reviewed and updated.	11.20.18	02.19
Added criteria preventing concurrent prescribing of Zolgensma; added criteria requiring medical justification, attestation, and evidence of clinical deterioration in members with a history of Zolgensma administration; added that member does not have respiratory insufficiency.	06.11.19	08.19
Changed initial approval duration from 6 months to 12 months and added quantity limit of 4 doses to allow for interruptions in administration of initial loading doses while still requiring an evaluation prior to transition into maintenance therapy.	10.09.19	11.19
1Q 2020 annual review: no significant changes; references reviewed and updated.	12.04.19	02.20
Amended re-authorization criteria to include validated functional tests: RHS, ULM, RULM, 6MWT; added objective parameters defining improvement in continuation criteria; specified that SMN2 gene test results should be dated within the past year with repeat test for confirmation.	02.13.20	5.20
Removed criteria requiring type of SMA, genetic tests within the last year, and repeat testing; amended language to require quantification of SMN2 copy number; amended re-authorization criteria to allow for medical justification.	07.07.20	08.20
Updated criteria language to restrict concomitant use with Evrysdi; references reviewed and updated.	08.25.20	11.20
1Q 2021 annual review: no significant changes; references reviewed and updated.	10.12.20	02.21
Added requirement for a trial of Evrysdi.	07.20.21	08.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.